The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Abstract
Purpose: The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1–positive, advanced solid tumor cohorts. Here, we present the results from the cohort of patients with advanced cervical cancer. Methods: Patients were treated with pembrolizumab 10 mg/kg every 2 weeks for up to 24 months. Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter. The primary end point was overall response rate per Response Evaluation Criteria in Solid Tumors, version 1.1, by investigator review. Safety was a secondary end point. Results: Twenty-four patients were enrolled in the cervical cancer cohort. The median age was 42 years (range, 26 to 62 years), 22 patients (92%) had received prior radiation therapy, and 15 patients (63%) had received two or more lines of therapy, including bevacizumab (10 of 24 patients), for advanced disease. At the data cutoff, median follow-up duration was 11.0 months (range, 1.3 to 32.2 months). Overall response rate was 17% (95% CI, 5% to 37%); four patients (17%) achieved a confirmed partial response, and three patients (13%) had stable disease. Median duration of response for the four patients who achieved a partial response was 5.4 months (4.1 to 7.5 months). Treatment related adverse events (AEs) were experienced by 18 patients (75%); only rash (n = 5; 21%) and pyrexia (n = 4; 17%) and occurred in ≥ 10% of patients. Five patients experienced grade 3 treatment-related AEs. No grade 4 treatment-related AEs or deaths were observed. Conclusion: In patients with programmed death ligand 1–positive advanced cervical cancer, pembrolizumab demonstrated antitumor activity and exhibited a safety profile consistent with that seen in other tumor types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,504
Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,121
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Lyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777
Monk, B. J., Sill, M. W., McMeekin, D. S., Cohn, D. E., Ramondetta, L. M., Boardman, C. H., Benda, J., & Cella, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8909 · Cited by 693
Moore, D. H., Blessing, J. A., McQuellon, R. P., Thaler, H. T., Cella, D., Benda, J., Miller, D. S., Olt, G., King, S., Boggess, J. F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.170 · Cited by 635
Long, H. J., Bundy, B. N., Grendys, E. C., Benda, J. A., McMeekin, D. S., Sorosky, J., Miller, D. S., Eaton, L. A., & Fiorica, J. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.021 · Cited by 556
Molecular mechanisms of cisplatin resistance in cervical cancer
Zhu, X., Zhu, H., Luo, H., Zhang, W., Shen, Z., & Hu, X. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s106412 · Cited by 407
Monk, B. J., Sill, M. W., Burger, R. A., Gray, H. J., Buekers, T. E., & Roman, L. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9043 · Cited by 346
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
Mezache, L., Paniccia, B., Nyinawabera, A., & Nuovo, G. J. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.108 · Cited by 311
Heeren, A. M., Punt, S., Bleeker, M. C., Gaarenstroom, K. N., van der Velden, J., Kenter, G. G., de Gruijl, T. D., & Jordanova, E. S. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.64 · Cited by 310
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Colombo, N., Carinelli, S., Colombo, A., Marini, C., Rollo, D., & Sessa, C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds268 · Cited by 281
Partlová, S., Bouček, J., Kloudová, K., Lukešová, E., Zábrodský, M., Grega, M., Fučíková, J., Truxová, I., Tachezy, R., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.4161/21624011.2014.965570 · Cited by 241
Khoja, L., Butler, M. O., Kang, S. P., Ebbinghaus, S., & Joshua, A. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0078-9 · Cited by 225
Changing paradigms in the systemic treatment of advanced cervical cancer
Pfaendler, K. S., & Tewari, K. S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.07.022 · Cited by 221
Muderspach, L. I., Blessing, J. A., Levenback, C., & Moore, J. L. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6024 · Cited by 118
Dolled-Filhart, M. P., Roach, C. M., Toland, G., Stanforth, D., Jansson, M., Lubiniecki, G. M., Ponto, G., & Emancipator, K. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0542-oa · Cited by 118
Santin, A. D., Sill, M. W., McMeekin, D. S., Leitão, M. M., Brown, J., Sutton, G. P., Le, L. V., Griffin, P. C., & Boardman, C. H. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.040 · Cited by 114
A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix
Schilder, R. J., Sill, M. W., Lee, Y.-C., & Mannel, R. S. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a83467 · Cited by 107
Hollebecque, A., Meyer, T., Moore, K. N., Machiels, J., Grève, J. D., López-Picazo, J. M., Oaknin, A., Kerger, J. N., Boni, V., Evans, T. R. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5504 · Cited by 98
Muggia, F. M., Blessing, J. A., Method, M. W., Miller, D. S., Johnson, G. A., Lee, R. B., & Menzin, A. W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.10.045 · Cited by 71
Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix
García, A. A., Blessing, J. A., Vaccarello, L., & Roman, L. D. (2007) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31803377c8 · Cited by 65
Cited by
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145
Chung, H. C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,069
Self-citationPembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Colombo, N., Dubot, C., Lorusso, D., Caceres, M. V., Hasegawa, K., Shapira-Frommer, R., Tewari, K. S., Salman, P., Hoyos Usta, E., Yañez, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2112435 · Cited by 1,067
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969
Self-citationEvolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Metadata
- Authors
- Frenel, J.-S., Le Tourneau, C., O’Neil, B., Ott, P. A., Piha-Paul, S. A., Gomez-Roca, C., van Brummelen, E. M. J., Rugo, H. S., Thomas, S., Saraf, S., Rangwala, R., & Varga, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-12-20
- Volume
- 35
- Issue
- 36
- Pages
- 4035-4041
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2766016099
- Cited by
- 531
- References
- 25
- FWCI
- 17.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.